Long-term ef®cacy and safety of Alprostadil-Alfadex (EDEX R /VIRIDAL R ) in intracavernous selfinjection therapy for chronical erectile failure was investigated in a four year running multicenter European trial. Of the 16 886 protocolled injections 93% (15 713) resulted in rigid erections followed by successful sexual intercourse. Reported side effects by patients were prolonged erections b 6 h only occurring during the ®rst year in 1.2% (2 out of 162), painful erections in 29% (47 out of 162) during the ®rst year and decreasing to 12.1% by year 4, hematomas, neither requiring therapeutic measures nor impeding sexual performance in 33.3% (54 out of 162) in year 1 with a decrease to 12.1% by year 4, ®brotic penile alterations such as nodules, plaques or deviations in 11.7% (19 out of 162) with spontaneous healing in 48% (9 out of 19). Of the 162 patients involved in this trial 54 completed the 4 y. Of the 54 completers 91.4% considered the tolerability good or very good and were satis®ed or very satis®ed with self-injection therapy with Alprostadil-Alfadex. The respective rates of the female partners were 51.7% very satis®ed and 39.7% satis®ed.
Introduction
Men who seek professional and medical help for erectile dysfunction generally have a low level of satisfaction with their sexual life and this, in turn, is highly predictive of their overall psychological status. 1 Successful treatment of the condition consequently enhances levels of life satisfaction, particularly with regard to the sexual quality of life of the patient and his partner. 2 As chronical erectile dysfunction impairs both partners and frequently jeopardizes stable relationships, the availability of an effective, reliable and also safe treatment becomes an essential issue. The intracavernosal injection of several vasoactive substances for the pharmacological management of erectile dysfunction is a highly effective and widely accepted technique already for a longer period. 3±5 Although a considerable number of vasoactive drugs have produced some erectile response both in animal and human in vivo and in vitro-trials, to date only three have found widespread clinical use, namely papaverine, the combination of papaverine/ phentolamine and PGE 1 (Alprostadil).
4±7
The multimodal biological activities of alprostadil substantiate the superior ef®cacy of this drug, that is, stimulation of adenylate cyclase with subsequent accumulation of 3 H 5 H -cAMP, presynaptical inhibition of noradrenaline release at alpha1-adrenoceptors resulting in a decrease of sympathetic tone and inhibition of angiotensin II secretion likewise reducing the contractile tone of cavernous smooth muscles. 6, 8, 9 This high ef®cacy together with its good safety pro®le has rendered Alprostadil the drug of choice and therefore the gold standard in self-injection therapy. 6,7,10±14 Compared to the other commonly used vasoactive drugs papaverine and the combination of papaverine/phentolamine Alprostadil demonstrated a higher ef®cacy and due to its rapid metabolism also a considerably lower incidence of prolonged erections b 6 h. 6,7,15±21 , Moreover, systemic sideeffects are rarely encountered with Alprostadil, probably due to the fact that it is naturally synthesized and at least partially metabolized within the cavernous bodies and, in addition, undergoes a rapid ®rst pass clearance in liver and lung tissue. In many studies the over-all rate of local ®brotic penile alterations was considerably lower after Alprostadil with 0±9% 6, 7, 18, 24 than after papaverine or the combination of papaverine/phentolamine with ®brosis-rates ranging between 30% and 51% in monoinstitutional series. 6 ,22±26 The objective of this present study was to provide for the ®rst time reliable data on a real long term use (4 y) of Alprostadil in a prospective multicenter trial according to the good clinical practice guidelines.
Subjects and methods
In this four year open-label study 162 patients with chronical erectile dysfunction longer than 1 y were enrolled. Inclusion criteria were a proven organogenic etiology or exceptionally a psychogenic etiology if psychosexual counselling for at least six months had failed. In addition, all patients had to be in a stable, heterosexual relationship. If a patient met all preconditions of inclusion-and exclusion criteria, he underwent a thorough diagnostic workup including medical history, physical examination and evaluation of the serum hormone levels of testosterone and prolactine, liver enzymes, glucose, creatinine, electrolytes and blood cell account. Following this, pharmaco-testing with increasing dosages of Alprostadil Alfadex up to 20 mg was performed until a rigid erection of more than 30 min suf®cient for sexual intercourse could be induced. The assessment of the erectile response was graded according to an erection assessment score 0±3, that is 0 no response, 1 tumescence, 2 full tumescence with partial rigidity (erectile angle 45±90 ) and 3 complete rigid erection (erectile angle b 90
). Patients achieving erection scores 2 and 3 were considered responders and provided with Alprostadil Alfadex for performance of sel®njection therapy.
All patients were thoroughly counselled on the purpose of the study and gave a written informed consent. The in-of®ce titration with Alprostadil Alfadex was combined with doppler or duplexsonography of the penile vessels in order to rule out or to prove impaired arterial in¯ow. Follow-up visits were arranged every two months during the ®rst three years and quarterly during the fourth year of the trial. At each visit the patient's diary with recording of all injections and virtual side-effects was examined followed by a penile check up with inspection and palpation. After every 12 months' of follow-up an intracavernous injection-test with the same dosage used at home, combined with a doppler/duplex sonography was carried out in order to evaluate eventual penile deviations and record changes in the penile blood¯ow. Also routine laboratory check-up and electrocardiogram were included in every 12 months' visit. Finally, both the patient and his spouse assessed tolerability and ef®cacy of self-injection therapy in a special questionnaire.
Results

Patients' demographics
The mean age of the 162 patients enrolled was 54 y (22±70) with a mean duration of erectile dysfunction of 4 y (1±37 y). 57.4% of the patients reported a complete incapacity for sexual intercourse, a total of 92.6% complained of incompletely rigid erections, 91.4% of inadequate duration of erection, 17.9% of simultaneous ejaculatory disorders and 7.4% of loss of libido. More than 85% (139) out of the 162 patients con®rmed negative effects of the erectile dysfunction on their personal relationships and 68% (110) of the female partners asserted a negative impact of erectile failure on partner-relationship. Prior to enrollment 43% (69) patients had tried several oral medications, prescribed by different physicians, 28% (45) performed self-medication with aphrodisiacs and 8% (13) had undergone vascular surgery such as penile revascularization procedures or penile venous surgery.
Etiology of erectile dysfunction
Based on history and especially on the diagnostic ®ndings purely psychogenic erectile dysfunction was found in only 15 (9.3%) of all patients. Considerable organogenic factors were detected in 147 (90.7%) patients with arterial insuf®ciency (Table 1) .
Patients' disposition
The disposition-data for each year are displayed in Table 2 . After one year of therapy three centers with a total of 23 patients had to be closed due to organizational reasons. Therefore only 81 patients entered the second year of the study. In the fourth year 58 (35.8%) out of the 162 patients continued and 54 (33.3%) patients completed the study accounting for a total drop-out rate of 66.7% after 4 y. The reasons for premature discontinuation were manifold and are exhibited in Table 3 . The drop-out rate during the second year to the end of the fourth year was 33.3%.
Ef®cacy and satisfaction
The primary ef®cacy variable of the trial was the ability of the patient to achieve a rigid erection after intracavernous injection suf®cient for vaginal penetration and performance of sexual intercourse. The number of successful injections followed by rigid erections and sexual intercourse increased from 90.7% in year 1 to 96.3% in year 4. 15 713 (93.1%) of 16 886 injections protocolled in the patient's diary resulted in sexual intercourse. (Table 4) The assessment of the 54 completers concerning ef®cacy and tolerability of self-injection therapy with Alprostadil are summarized in Table 5 . The completers' satisfaction-rates were more than 98% at termination of the study.
Impact on personality and partner-relationship
The respective assessments of the positive impact of self-injection therapy both on self-esteem, personality and partner relationship are represented in Table 6 for each year of the study.
Adverse events
Typical adverse events linked to self-injection therapy and/or the drug itself are prolonged erections, hematomas, false injections, painful sensations and local ®brotic alterations. The respective numbers of these adverse events are summarized for each year in Table 7 showing a considerable decrease for all events in the course of the study which re¯ects an increased experience of the patient with the handling of self-injection therapy. The two episodes of prolonged erections required the intracavernous injection of an alpha-adrenergic antidote.
Fibrotic changes
A very special issue in self-injection therapy is the occurrence of local ®brotic changes such as nodules, plaques, ®brosis with or without associated penile curvatures. Table 8 displays the extent and outcome of the 19 (11.7%) ®brotic alterations. The date of ®rst detection of these ®brotic changes by the investigator was at average twelve months (range 4±36 months) and the average number of injections 62 (range 16±132). After 4 y of self-injection therapy 9 out of these 19 cases exhibited a spontaneous healing due to temporary discontinuation with subsequent reuptake of self-injection therapy and reassurance of correct self-injection therapy-technique. Only 8 (4.9%) out of 162 patients revealed persistent ®brotic changes, in two further cases the outcome is unclear due to loss of follow-up.
Systemic, drug-related adverse events
Neither in the clinical examinations including ECG, nor in the laboratory exams systemic side-effects were encountered.
Penile duplex/doppler ®ndings
The results of the doppler/duplex examinations conducted at the onset and after completion of the study demonstrated an increase of normal ®ndings from 55% to about 80% for both deep penile arteries implying a considerable improvement of penile blood¯ow in the long-term course of Alprostadil self-injection therapy. (Table 9 )
Discussion
Therapeutic strategies for erectile dysfunction of varied etiology comprise a wide range of facilities reaching from oral drug therapy to penile implants. The chosen option for any treatment is depending on the patient's and his partner's preference and on the underlying etiology. The overwhelming majority of the af¯icted couples primarily opt for the least invasive therapy typically represented by oral or topical pharmacotherapy. Up to the present time yohimbine was the only available oral drug, of which the ef®cacy has been assessed in a considerable number of placebo-controlled as well as noncontrolled trials with controversial results. A recently published systematic review and metaanalysis of randomised clinical trials with yohimbine resulted in the conclusion that its bene®t seems to outweigh its risks. 27 The clinical guidelines panel on erectile dysfunction however concluded that yohimbine does not appear to be effective for 14 The same guidelines panel recommended three treatment alternatives for erectile dysfunction: vacuum constriction devices, vasoactive drug injection therapy and penile prosthesis implantation and proclaimed that prostaglandin E 1 (Alprostadil) monotherapy should be the preferred initial therapy. This recommendation is impressively supported by the outcome of the present long-term study with success-rates of more than 92% in home use and satisfaction-rates of patients and partners in the same range after 4 y of treatment. In addition systemic side-effects were not observed and prolonged erections b 6 h occurred in only 1% in the inital titration-phase but not in long-term home use. Although pain with Alprostadil application was reported in a total of 29% in at least one application, these painful sensations used to be mild not preventing patients from sexual intercourse.
A special concern in self-injection therapy is the manifestation of local ®brotic changes. These occurred in a total of 11.7% of the patients, however, a spontaneous healing rate of 47% was observed, so that only 5% of these ®brotic changes persisted. Comparable ®gures were communicated by Linet and Ogrinc 28 with 33% spontaneous healing rates of penile ®brosis in US-Caverject Rtrials. The home-success rates with about 90% as well as the risk of prolonged erections ( $ 1%) and penile ®brosis (7±9% after 18 months) were similar and therefore comparable to our study, 28, 29 especially from the standpoint of ef®cacy and tolerability the results of the various quoted Alprostadil studies are much more favourable than these reported in retrospective trials with papaverine or the mixture of papaverine and phentolamine. 6, 22, 23, 25, 26 The doppler/duplex examinations in the present series provided evidence of a considerable improvement of arterial penile blood¯ow in long-term use of Alprostadil re¯ected by the 25% increase of normal ®ndings in the deep penile arteries (Table 9 ). Similar observations in a smaller group of patients (n 35) were published by Marshall et al 30 who found an increase of 33% and 37% in the peak¯ow velocities of the cavernous arteries after a mean of 31 months of treatment with Alprostadil or combinations of it.
No other vasoactive drug demonstrated such improvements of penile arterial blood¯ow in doppler/duplex measurements, as reported in the literature so far. A considerable shortcoming of selfinjection therapy represents the high drop-out rate which amounts to about 50% after 24 months irrespective of the drug used so far. 5, 6 A strong argument against injection therapy is needle-phobia of many patients together with the somewhat complicated handling of Alprostadil injection that means the necessity of reconstitution of the drug preparation associated with different needle sizes.
In order to reduce these drawbacks a new carpule system for intracavernosal delivery of Alprostadil Alfadex (Viridal R /Edex R ) was recently developed which avoids the need for drug reconstitution and needle change (Figures 1±3) and seems to have reasonable advantages to the conventional application devices. Completely different from self injection therapy is the intraurethral Alprostadil application introduced by Padma Nathan.
31
Due to its at ®rst sight very simply looking technical handling with a user friendly applicator system many patients primarily prefer this new therapeutic option. But the ®rst reports in favour for intraurethral Alprostadil 31 were disproven by the publications of Porst 32 and Werthman and Rajfer 33 both of them providing convincing evidence on its inferior ef®cacy and higher side-effect rate linked to the MUSE R application with only 10% and 7% Intracavernous Alprostadil Alfadex H Porst et al well-sustained rigid erections in an in-of®ce setting compared to 48% and 49%, respectively, after intracavernous application of up to 20 mg Alprostadil. A special concern with intraurethral application is the provocation of urethral bleeding in 3±6% and blood pressure decay with syncopal episodes in 1±2%.
31±35
In terms of the occurrence of penil ®brosis intraurethral application seems to be less risky with 3.8% after 15 months of follow-up in the European study compared to 5.7% in the self-injection studies with Alprostadil for the same period. 28, 29, 35 The most reliable parameter for assessment of ef®cacy and acceptance of a new therapy in any ®eld of medicine represents the drop-out rate in longterm observation. Although the drop out rates in the different prospective self-injection trials with Alprostadil ranged between 50 and 55% after 18±24 months the respective drop-out rate in the European MUSE R study was 75% of 249 involved patients after 15 months and was therefore considerably higher than in the self-injection trials. 29, 35 Taking all these facts into account self-injection therapy represents furthermore the more effective and reliable therapeutic option and remains the gold standard whereas intraurethral application will meet the patient's and partner's expectancies for long-term reliability and ef®cacy in only 25%. Although new, promising oral drugs like Sildena®l, 36 Apomorphine 37 and oral Phentolamine mesylate 38 are under consideration in different trials and may soon be available, all of them will be able to cover only a part of these patients who would be otherwise candidates for self-injection therapy, which means that self-injection therapy with Alprostadil or other vasoactive drugs will continue to be a corner-stone in the management of male impotence. 
